Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2021 financial results and to provide a corporate update.

Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021

CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Sarepta) (Nasdaq:SRPT) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC Capital) to purchase up to 2,000,000 shares of Sarepta common stock at a price of $68.50 per share in cash. TRC Capital's offer price is approximately 4.6% lower than the closing share price of Sarepta's common stock on April 16, 2021, the last business day prior to the commencement of the offer. The offer is for approximately 2.52% of the shares of Sarepta common stock outstanding.

Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

We believe that the stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is undervalued at current levels of $71. SRPT stock is down 20% off the March 2020 bottom compared.

Should You Buy Sarepta Stock At $71?

AstraZeneca

Biogen

Johnson & Johnson

Moderna

Pfizer

Vertex Pharmaceuticals

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.

Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas

SRPT stock has some positives going for it but its underlying gene therapy solutions have questions that investors can't shake. The post Positive Spin Isn't Working for Sarepta Therapeutics appeared first on InvestorPlace.

Positive Spin Isn't Working for Sarepta Therapeutics

A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.

Is Sarepta Therapeutics Worthy of Redemption?

While revenue continues to grow, the biotech's future hinges on its gene therapy SRP-9001.

Sarepta Therapeutics' Long-Term Potential Is in Flux

Dyne Therapeutics

PTC Therapeutics

Avidity Biosciences

Solid Biosciences

Edgewise Therapeutics has filed to raise $150 million in an IPO.

Edgewise Therapeutics Proposes Terms For $150 Million IPO

We believe that ​Sarepta Therapeutics stock, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying opportunity at the present time. SRPT stock trades near $83 currently and it is, in fact.

Should You Buy Sarepta Therapeutics Stock For 50% Gains?

-- Application website is now open for the 2021 Scholarship Program -- -- The Company will award up to 15 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program

An experimental gene therapy from Sarepta Therapeutics showed "remarkable" stability at two years in muscular dystrophy patients, an analyst said Friday as SRPT stock edged higher. The post Can Sarepta's 'Remarkable' Gene Therapy Pull Shares Out Of The Dumps?

Can Sarepta's 'Remarkable' Gene Therapy Pull Shares Out Of The Dumps?

The gene therapy, known as SRP-9003, treats a disorder called limb-girdle muscular dystrophy type 2E.

Sarepta Stock Has Been Battered. Positive Gene Therapy Data Sends Shares 5% Higher.

-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as measured by western blot -- -- Mean NSAD score improvement of 5.7 points from baseline was sustained through 24 months in low-dose cohort, and mean NSAD score improvement of 4.0 points from baseline at one year in high-dose cohort -- -- Results in both cohorts continue to reinforce the safety and tolerability profile of SRP-9003 -- CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new results from the ongoing study of SRP-9003 (rAAVrh74.MHCK7.hSGCB), the Company's investigational gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E). In the first look at expression data from biopsies taken two years after a single administration of SRP-9003, results found sustained protein expression in muscle tissue. In functional outcomes assessments taken two years following treatment in Cohort 1 (low-dose cohort) and one year after treatment in Cohort 2 (high-dose cohort), patients continued to demonstrate stability in their NSAD (North Star Assessment for Dysferlinopathies) total score and improvements on timed function tests. Results are being presented today at the 2021 Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference.

Sarepta Therapeutics' Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

SRPT's lucrative Exon-Skipping franchise allows the company to buy a second chance, even if its SRP 9001 project fails.

Exon-Skipping Franchise Buys Sarepta A Second Chance

-- Ten abstracts, including four podium presentations, reflect Sarepta's ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions -- CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, which will take place virtually March 15-18, 2021. Among the research that will be presented:

Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference

Centene

Neurocrine Biosciences

Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years, although their stock prices have lagged, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines.

Centene, Neurocrine, Sarepta: Will These Out Of Favor Healthcare Stocks Outperform?

Cowen

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Cowen 41st Annual Health Care Conference (Transcript)

Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels[Updated 3/2/2021] Sarepta Update Last month we talked about how Sarepta Therapeutics stock (NASDAQ: SRPT) seems to be a good buying opportunity, given a large sell-off, and now there have been some positive developments for the.

Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta Therapeutics stock fell as markets digested its bigger-than-expected quarterly loss. But analysts say the setup for the stock remains positive.

Sarepta Therapeutics Drops on Earnings. Why Analysts Remain Hopeful.

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2020 Results - Earnings Call Transcript

Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 17.20% over the past year to ($1.84), which missed the estimate of ($1.77).

Recap: Sarepta Therapeutics Q4 Earnings

– Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference –

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.

Earnings Preview: Sarepta Therapeutics

Shares of Sarepta Therapeutics Inc. rose nearly 1% in late trading Thursday after the biotech company said the U.S. Food and Drug Administration has approved one of its treatments for Duchenne muscular dystrophy in patients with certain mutations. The continued approval of the injection, called amondys 45, could be contingent on confirmation of a clinical benefit in further trials, Sarepta said.

News for Sarepta Therapeutics Stock (SRPT)